DNTH
Dianthus Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$108.10
+0.23%Year over year
Reported trailing growth
- Revenue
- -60.8%
- EBITDA
- +75.9%
- EBIT
- -67.7%
- EPS
- +96.0%
- Free cash flow
- -55.2%
- Operating cash flow
- -55.0%
Forward estimates
Based on analyst estimates
- Revenue
- -16.3%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -31.8%
- EBITDA
- -91.5%
- EBIT
- -74.7%
- Net income
- -91.1%
- EPS
- -64.7%
- Free cash flow
- -65.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026